Patel, K., Shah, G., Schoder, H., Ganesan, N., Drill, E., Hancock, H., Davey, T., Santarosa, A., Galasso, N., Kumar, A., Lahoud, O., Hamlin, P., Owens, C., Caron, P., Intlekofer, A., Horwitz, S., Falchi, L., Johnson, W., Palomba, L., Noy, A., Matasar, M., Salles, G., Vardhana, S., Keudell, G. V., Yahalom, J., Dogan, A., Zelenetz, A., Moskowitz, C., Moskowitz, A. (2025). Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial. Blood. https://doi.org/10.1182/blood-2025-1850